DPP-4
Assets acting on this target.
- Class
- Dipeptidyl peptidase-4 inhibitor
Dipeptidyl peptidase-4 (DPP-4) is an enzyme present on the surface of many cell types and circulating in blood, where it rapidly breaks down a class of gut-derived hormones called incretins, principally glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones are released after meals and help the pancreas release insulin in a glucose-dependent manner while suppressing glucagon, a hormone that raises blood sugar. By inhibiting DPP-4, drugs in this class prolong the activity of endogenous incretins, leading to improved insulin secretion and reduced glucagon output after eating, without directly stimulating insulin release independent of glucose levels. This mechanism is central to the management of type 2 diabetes, where impaired incretin signaling and insulin resistance contribute to elevated blood glucose. Because DPP-4 inhibition works through amplifying a natural, glucose-sensitive pathway rather than forcing insulin release, it is generally associated with a lower risk of hypoglycemia compared to some older glucose-lowering approaches. The enzyme's broad distribution across immune, renal, and endothelial tissue also underlies ongoing interest in effects beyond glycemic control, though the primary rationale for this drug class remains restoration of postprandial incretin activity in diabetes care.
By indication
Related mechanisms
DPP-4 drugs compared
17 drugs, stage by indication
| Drug | Developer | Modality | Furthest stage | Stage by indication |
|---|---|---|---|---|
| AlogliptinNesina | Takeda Pharmaceutical Company, Teijin | small molecule | Approved | Approved in Type 2 Diabetes |
| LinagliptinTradjenta | Boehringer Ingelheim, Eli Lilly | small molecule | Approved | Approved in Type 2 Diabetes |
| SaxagliptinOnglyza | AstraZeneca, Kyowa Kirin | small molecule | Approved | Approved in Type 2 Diabetes |
| SitagliptinJanuvia | Merck & Co., Ono Pharmaceutical | small molecule | Approved | Approved in Type 2 Diabetes |
| AnagliptinSuiny | JW Pharmaceutical, Kowa Company, Ltd., Sanwa Kagaku Kenkyusho | small molecule | Phase 3 | Phase 3 in Type 2 Diabetes |
| Cofrogliptin | Haisco Pharmaceutical Group | small molecule | Phase 3 | Phase 3 in Type 2 Diabetes |
| EvogliptinSuganon | Alkem Laboratories, Dong-A ST, Eurofarma Laboratorios, Geropharm, Luye Pharma Group, Rednvia | small molecule | Phase 3 | Phase 3 in Type 2 Diabetes |
| GemigliptinZemiglo | China Resources Double-Crane Pharmaceutical, Daewoong Pharmaceutical, LG Chem, Sanofi, Stendhal | small molecule | Phase 3 | Phase 3 in Type 2 Diabetes |
| Gosogliptin | SatRx | small molecule | Phase 3 | Phase 3 in Type 2 Diabetes |
| OmarigliptinMarizev | Kissei Pharmaceutical, Merck & Co. | small molecule | Phase 3 | Not recorded |
| PrusogliptinShanzeping | CSPC Pharmaceutical Group, Genovate Biotechnology | small molecule | Phase 3 | Phase 3 in Type 2 Diabetes |
| Retagliptin | Jiangsu Hengrui Pharmaceuticals | small molecule | Phase 3 | Phase 3 in Type 2 Diabetes |
| TeneligliptinTenelia | Handok, Servier, Tanabe Pharma Corporation | small molecule | Phase 3 | Phase 3 in Type 2 Diabetes |
| TrelagliptinZafatek | Takeda Pharmaceutical Company, Teijin | small molecule | Phase 3 | Phase 3 in Type 2 Diabetes |
| VildagliptinGalvus | Cipla, Novartis, Sumitomo Pharma | small molecule | Phase 3 | Phase 3 in Type 2 Diabetes |
| Yogliptin | Chengdu Easton Biopharmaceuticals | small molecule | Phase 3 | Phase 3 in Type 2 Diabetes |
| Retagliptin/metformin (Ruilintang)Ruilintang | Jiangsu Hengrui Pharmaceuticals | small molecule combination | Phase 1 | Phase 1 in Type 2 Diabetes |